8-K: Donaldson Reports Record Adjusted Q3 Earnings, Raises Full-Year EPS Guidance Despite Bioprocessing Impairment

Donaldson Company, Inc. announced record adjusted third-quarter sales and EPS, raised its full-year adjusted EPS guidance, and increased its quarterly dividend, despite a significant non-recurring charge for intangible asset impairment in its bioprocessing businesses.

Summary

• Donaldson reported third quarter fiscal 2025 GAAP net earnings of $57.8 million, a significant decrease from $113.5 million a year ago, resulting in GAAP EPS of $0.48 compared to $0.92 in 2024.
• These GAAP results include $65.8 million of pre-tax, non-recurring net charges, with $62.0 million specifically for the impairment of certain intangible assets related to two upstream bioprocessing businesses (Univercells Technologies and Solaris).
• Excluding these items, adjusted third quarter net earnings were $118.9 million, up 4.8% compared with the prior year, and adjusted EPS was $0.99, a 7.6% increase versus 2024.
• Total sales for the third quarter were $940.1 million, an increase of 1.3% compared with 2024, driven by pricing benefits and volume growth.
• Mobile Solutions segment sales decreased 0.4% (increased 0.2% in constant currency), with On-Road sales down 24.5% and Off-Road sales down 8.3% due to ongoing market weakness, while Aftermarket sales rose 3.3%.
• Industrial Solutions segment sales increased 5.3%, primarily driven by a 27.1% growth in Aerospace and Defense sales and a 1.4% rise in Industrial Filtration Solutions (IFS) sales.
• Life Sciences segment sales increased 0.7%, supported by Disk Drive market strength and Food and Beverage replacement part sales, partially offset by unfavorable timing of bioprocessing sales.
• Gross margin was 34.2%, down from 35.6% in 2024 due to higher manufacturing costs and footprint optimization initiatives; adjusted gross margin was 34.5%.
• Operating expenses as a percentage of sales increased to 24.9% from 20.1% due to non-recurring charges; adjusted operating expenses as a percentage of sales improved to 18.2%.
• Operating income as a percentage of sales was 9.3% compared with 15.5% in 2024; adjusted operating margin was 16.3%, an 80-basis point year-over-year increase.
• The company repurchased 2.4% of its shares outstanding for $192.4 million during the third quarter, bringing year-to-date repurchases to 3.3% of outstanding shares for $273.8 million.
• Donaldson announced an 11% increase to its quarterly dividend.
• The company narrowed its fiscal 2025 adjusted full-year EPS guidance to between $3.64 and $3.70, with the midpoint $0.03 above prior guidance.
• Fiscal 2025 sales are forecast to increase 1% to 3% year over year, consistent with previous expectations, with pricing contributing one percentage point.

Sentiment

Score: 7

Explanation: While GAAP earnings were significantly impacted by a one-time intangible asset impairment charge, the adjusted results show strong underlying performance with record adjusted sales and EPS. The company's decision to raise full-year adjusted EPS guidance, increase dividends, and accelerate share repurchases reflects confidence in its core business and future outlook, despite challenges in specific bioprocessing markets.

Positives

• Reported record adjusted third quarter sales of $940.1 million and record adjusted earnings per share of $0.99.
• Adjusted net earnings increased by 4.8% and adjusted EPS by 7.6% year-over-year, demonstrating strong underlying business performance.
• Raised full-year adjusted EPS guidance to a range of $3.64 to $3.70, with the midpoint $0.03 higher than previous guidance, indicating improved profitability outlook.
• Accelerated share repurchase program, buying back 2.4% of shares outstanding for $192.4 million in Q3, and 3.3% year-to-date for $273.8 million, returning capital to shareholders.
• Announced an 11% increase to the quarterly dividend, reflecting confidence in future cash flow and commitment to shareholder returns.
• Aftermarket sales within the Mobile Solutions segment rose 3.3%, driven by robust OE channel demand and market share gains in the independent channel.
• Aerospace and Defense sales grew significantly by 27.1% due to strong end-market conditions.
• Industrial Filtration Solutions (IFS) sales increased 1.4%, primarily from strength in replacement part sales across several key businesses.
• Life Sciences segment sales increased 0.7%, supported by healthy market demand in Disk Drive and Food and Beverage replacement parts.
• Adjusted operating expenses as a percentage of sales improved by 190 basis points year-over-year, driven by expense discipline and a reversal of an earn-out reserve.
• Adjusted operating margin increased by 80 basis points year-over-year to 16.3%, reflecting improved operational efficiency.
• Fiscal 2025 adjusted operating margin is expected to improve to between 15.6% and 16.0%.

Negatives

• GAAP net earnings decreased by 49.1% to $57.8 million and GAAP diluted EPS by 48.0% to $0.48 year-over-year.
• Incurred $65.8 million of pre-tax, non-recurring net charges, including a significant $62.0 million charge for the impairment of intangible assets related to two upstream bioprocessing businesses (Univercells Technologies and Solaris).
• Mobile Solutions segment sales declined 0.4% overall, with significant decreases in On-Road sales (down 24.5%) and Off-Road sales (down 8.3%) due to ongoing weakness in transportation and agriculture markets.
• Gross margin decreased to 34.2% from 35.6% in the prior year, attributed to higher manufacturing costs and footprint optimization initiatives.
• Operating expenses as a percentage of sales increased substantially to 24.9% from 20.1% in the prior year, primarily due to the non-recurring impairment and restructuring charges.
• The effective tax rate increased to 33.6% from 21.2% a year ago.
• Weak bioprocessing capital spending and longer drug development timelines contributed to the significant intangible asset impairment charges in the Life Sciences segment.
• Unfavorable timing of bioprocessing sales partially offset growth in the Life Sciences segment.

Risks

• Challenges in global operations.
• Impacts of global economic, industrial, and political conditions on product demand.
• Impacts from unexpected events, including natural disasters.
• Effects of unavailable raw materials or material cost inflation.
• Inability to attract and retain qualified personnel.
• Inability to meet customer demand.
• Inability to maintain competitive advantages.
• Threats from disruptive technologies.
• Effects of highly competitive markets with pricing pressure.
• Exposure to customer concentration in certain cyclical industries.
• Inability to manage productivity improvements.
• Inability to achieve commitments to ESG (Environmental, Social, and Governance).
• Results of execution of any acquisition, divestiture, and other strategic transactions.
• Vulnerabilities associated with information technology systems and security.
• Inability to protect and enforce intellectual property rights.
• Costs associated with governmental laws and regulations.
• Impacts of foreign currency fluctuations.
• Effects of changes in capital and credit markets.

Future Outlook

Donaldson narrowed its fiscal 2025 adjusted full-year EPS guidance to between $3.64 and $3.70, with the midpoint $0.03 above prior guidance. Sales are forecast to increase 1% to 3% year over year, with pricing expected to contribute one percentage point. Mobile sales are projected to be flat to up 2%, with Off-Road sales declining mid-single digits and On-Road sales decreasing high teens, while Aftermarket sales are expected to grow low-single digits. Industrial sales are forecast to increase between 2% and 4%, with IFS sales growing low-single digits and Aerospace and Defense sales increasing low teens. Life Sciences sales are projected to grow high-single digits. Adjusted 2025 operating margin is expected to improve to between 15.6% and 16.0%. Capital expenditures are forecast to be between $75 million and $90 million, and adjusted free cash flow conversion is expected to be between 80% and 90%. The company anticipates repurchasing between 3.5% and 4.0% of its shares outstanding for the full year.

Management Comments

• Tod Carpenter, chairman, president and chief executive officer: "I am proud of our third quarter earnings results which are a testament to the durability of our business model and the strength of the Donaldson team."
• Tod Carpenter, chairman, president and chief executive officer: "Showing our company strength, we reported record sales and record adjusted earnings per share, raised full-year adjusted earnings per share guidance, accelerated share repurchase to 3.3% of outstanding shares year-to-date, and recently announced an 11% increase to our quarterly dividend."
• Tod Carpenter, chairman, president and chief executive officer: "For the full year, we expect to generate record sales and adjusted earnings. Importantly, our region-for-region footprint combined with the speed of decision making following our organizational redesign contribute to our expectation that the net impact on earnings from current tariffs will be immaterial."
• Tod Carpenter, chairman, president and chief executive officer: "Rich is an experienced leader with a track record of consistent operational success through a broad range of dynamic and challenging market conditions. During his 23 years with Donaldson, he has achieved a deep understanding of our global portfolio of businesses, end markets, and customers needs. I look forward to partnering with Rich to further strengthen execution of our strategy and drive value creation for all of our stakeholders."
• Richard Lewis, Chief Operating Officer: "I am honored to step into the COO role and lead operations for the company’s diversified portfolio of businesses. I am eager to continue working with our strong leadership team to deliver our innovative solutions for customers around the globe and further our collective success."

Industry Context

The filing highlights mixed industry conditions impacting Donaldson's segments. The Mobile Solutions segment continues to face ongoing weakness in transportation and agriculture markets, leading to declines in Off-Road and On-Road sales. Conversely, the Aerospace and Defense sector is experiencing robust end-market conditions, driving significant growth for Donaldson. The Life Sciences segment is affected by weak bioprocessing capital spending and longer drug development timelines, leading to significant intangible asset impairment charges, indicating a challenging environment for new bioprocessing equipment. However, the segment benefits from healthy demand in Disk Drive and Food & Beverage replacement parts, suggesting resilience in certain sub-sectors. The overall strength in replacement parts across various businesses (Aftermarket, IFS) indicates a stable demand for maintenance and consumables, which is a positive trend for filtration companies.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess Donaldson's performance against global industry benchmarks. The analysis is focused solely on Donaldson's internal financial and operational performance.

Management Changes

Stakeholder Impact

• Shareholders: Likely positive impact due to increased dividend, accelerated share repurchases, and raised adjusted EPS guidance, signaling strong returns and management confidence. However, the significant GAAP earnings decline due to impairment may cause some concern.
• Employees: Richard B. Lewis's promotion to COO indicates internal career progression opportunities. The ongoing cost and footprint optimization efforts mentioned could imply operational adjustments affecting some employees.
• Customers: Continued focus on technology-led filtration products and solutions, with strong performance in Aftermarket and Aerospace & Defense, suggests reliable product availability and service. Weakness in new equipment sales in certain areas (e.g., bioprocessing, On-Road/Off-Road) might affect specific OEM customers.
• Suppliers: Higher manufacturing costs were noted, but no direct specific impact on suppliers was detailed in the filing.
• Creditors: The company's financial position appears stable with strong adjusted free cash flow conversion, although there was an increase in long-term debt and short-term borrowings.

Next Steps

• Donaldson Company, Inc. will webcast its third quarter fiscal 2025 earnings conference call on June 3, 2025, at 9:00 a.m. CT.
• A webcast replay will be available at approximately 12:00 p.m. CT on June 3, 2025, on Donaldson's Investor Relations website.
• The company's supplemental quarterly earnings presentation will also be available on its investor relations website.
• Richard B. Lewis's appointment as Chief Operating Officer will become effective on August 1, 2025.
• A successor for the role of President, Life Sciences, currently held by Richard Lewis, will be named.
• The company will file its results with the United States Securities and Exchange Commission on Form 10-Q.

Key Dates

Recommendation

Keywords

Filtration, Industrial Filtration, Mobile Solutions, Life Sciences, Bioprocessing, Air Filtration, Liquid Filtration, Engine Filtration, Dust Collection, Aerospace and Defense, Aftermarket, OEM, Financial Results, Earnings, EPS, Dividend, Share Repurchase, Intangible Asset Impairment, Corporate Governance